Remifentanil Acid | 132875-68-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Remifentanil Acid
• 英文别名: 3-[4-methoxycarbonyl-4-(N-propanoylanilino)piperidin-1-yl]propanoic acid
• CAS: 132875-68-4
• 化学式: C₁₉H₂₆N₂O₅
• 分子量: 362.4
• InChiKey: GFJKFSFFMHOISI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  87.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-(2-tert-Butoxycarbonyl-ethyl)-4-(phenyl-propionyl-amino)-piperidine-4-carboxylic acid methyl ester 生成 Remifentanil Acid
  参考文献：
  名称：

  J. Med. Chem. 1991, 34, 2202-2208

  摘要：

  DOI：

文献信息

• [EN] FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING<br/>[FR] HAPTÈNES DE FENTANYL, CONJUGUÉS D'HAPTÈNE DE FENTANYL, ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：UNIV MINNESOTA

  公开号：WO2021183913A1

  公开（公告）日：2021-09-16

  This disclosure describes fentanyl haptens, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten-carrier conjugate including, for example, as a prophylactic vaccine to counteract toxicity from exposure to fentanyl, fentanyl derivatives, and fentanyl analogs. In some embodiments, the fentanyl hapten-carrier conjugate or a composition including the fentanyl hapten-carrier conjugate may be used in an anti-opioid vaccine.

  这份披露描述了芬太尼半抗原、芬太尼半抗原载体共轭物，制备芬太尼半抗原载体共轭物的方法，以及使用芬太尼半抗原载体共轭物的方法，例如作为一种预防性疫苗来对抗暴露于芬太尼、芬太尼衍生物和芬太尼类似物所产生的毒性。在某些实施方式中，芬太尼半抗原载体共轭物或包含芬太尼半抗原载体共轭物的组合物可用作抗阿片类药物的疫苗。
• Process for producing a N-phenyl-N-(4-piperidinyl) amide derivative
  申请人：GLAXO GROUP LIMITED

  公开号：EP0638554A1

  公开（公告）日：1995-02-15

  A process for the preparation of the compound of formula (I), a useful intermediate for the preparation of analgesic agents. which comprises reacting a compound of formula (II) or an acid addition salt thereof with propionic anhydride and then treating the resultant product with methanol.

  一种制备式 (I) 化合物的工艺，它是制备镇痛剂的有用中间体。 其中包括使式（II）化合物或其酸加成盐反应 与丙酸酐反应，然后用甲醇处理生成物。
• Abuse-proofed dosage form
  申请人：GRÜNENTHAL GMBH

  公开号：US10058548B2

  公开（公告）日：2018-08-28

  The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.

  本发明涉及一种热成型而不变色并可防止滥用的剂型，它包括至少一种断裂强度至少为 500 N 的合成或天然聚合物，以及一种或多种可能被滥用的活性物质。本发明还涉及生产上述剂型的相应方法。
• Compositions and methods for reducing overdose
  申请人：Odidi Isa

  公开号：US10293046B2

  公开（公告）日：2019-05-21

  Drug delivery formulations, uses thereof and methods of making same are provided in order to reduce the potential for abuse, misuse or improper administration of an addictive substance or any active substance and to prevent, reduce, inhibit, or delay purposeful or accidental overdose of an active substance by ingesting too many dosage forms at once, for example.

  提供给药制剂、其用途和制作方法是为了减少滥用、误用或不当使用成瘾物质或任何活性物质的可能性，并防止、减少、抑制或延缓因一次摄入过多剂型的活性物质而有目的或意外地过量使用。
• Abuse resistant capsule
  申请人：R.P. Scherer Technologies, LLC

  公开号：US10420729B2

  公开（公告）日：2019-09-24

  The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquilizers, stimulants and narcotics.

  本发明涉及一种速释和缓释胶囊或胶囊填充剂，它可减少通过直接静脉注射滥用易滥用的活性药物成分。填充物包括一种肠外抗滥用液体制剂，当与水混合并加热时，会产生一种浑浊、粘稠或起泡的混合物，不能用标准胰岛素注射器注射。抗滥用活性药物成分选自阿片类、阿片类、镇静剂、兴奋剂和麻醉剂。